|
|
Biomolecular Analysis using Liquid Crystals
|
5R01CA108467-04
|
$433,274
|
$433,274
|
ABBOTT, NICHOLAS
|
UNIVERSITY OF WISCONSIN MADISON
|
|
|
SPORE in Pancreatic Cancer
|
5P20CA101936-05
|
$1,042,511
|
$312,753
|
ABBRUZZESE, JAMES
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
|
Discovery of Alpha-MSH Analogs for Skin Cancer Prevention
|
5R01CA114095-02
|
$302,740
|
$302,740
|
ABDEL-MALEK, ZALFA
|
UNIVERSITY OF CINCINNATI
|
|
|
Optical Probes & Methods for Imaging Integrin Expression
|
5R01CA109754-04
|
$570,346
|
$142,587
|
ACHILEFU, SAMUEL
|
WASHINGTON UNIVERSITY
|
|
|
Radioactive Nanoparticle Immunoconjugates for the Treatment of Solid Tumors
|
1R21CA128421-01
|
$171,000
|
$171,000
|
ADAMS, GREGORY
|
FOX CHASE CANCER CENTER
|
|
|
Children's Oncology Group Phase 1 / Pilot Consortium
|
2U01CA097452-06
|
$2,573,434
|
$2,573,434
|
ADAMSON, PETER
|
NATIONAL CHILDHOOD CANCER FOUNDATION
|
|
|
Prostate cancer prevention and treatment by sillibinin
|
5R01CA102514-05
|
$322,762
|
$322,762
|
AGARWAL, RAJESH
|
UNIVERSITY OF COLORADO DENVER/HSC AURORA
|
|
|
Clinical and Immunologic Evaluation of ProstAtak for Prostate Cancer
|
1R44CA124032-01A1
|
$101,130
|
$101,130
|
Aguilar-Cordova, Estuardo
|
ADVANTAGENE, INC
|
|
|
Participation in the Eastern Cooperative Oncology Group
|
5U10CA107868-04
|
$234,166
|
$21,075
|
AISNER, JOSEPH
|
UNIV OF MED/DENT NJ-R W JOHNSON MED SCH
|
|
|
Defining the role of Id1 in melanoma development
|
5R01CA107017-04
|
$244,169
|
$122,085
|
ALANI, RHODA
|
JOHNS HOPKINS UNIVERSITY
|
|
|
Arizona Cancer Center Support Grant
|
3P30CA023074-30S1
|
$363,313
|
$65,396
|
ALBERTS, DAVID
|
UNIVERSITY OF ARIZONA
|
|
|
Arizona Cancer Center Support Grant
|
3P30CA023074-30S2
|
$113,227
|
$20,381
|
ALBERTS, DAVID
|
UNIVERSITY OF ARIZONA
|
|
|
Arizona Cancer Center Support Grant
|
3P30CA023074-30S3
|
$327,884
|
$59,019
|
ALBERTS, DAVID
|
UNIVERSITY OF ARIZONA
|
|
|
Arizona Cancer Center Support Grant
|
3P30CA023074-30S4
|
$88,172
|
$15,871
|
ALBERTS, DAVID
|
UNIVERSITY OF ARIZONA
|
|
|
CHEMOPREVENTION OF SKIN CANCER PROGRAM PROJECT
|
5P01CA027502-26
|
$3,758,432
|
$1,315,451
|
ALBERTS, DAVID
|
UNIVERSITY OF ARIZONA
|
|
|
Arizona Cancer Center Support Grant
|
5P30CA023074-30
|
$4,124,404
|
$742,393
|
ALBERTS, DAVID
|
UNIVERSITY OF ARIZONA
|
|
|
High Resolution Genomic Analysis of Amplicon Structure
|
3R01CA090421-03S2
|
$45,000
|
$15,750
|
Albertson, Donna
|
UNIVERSITY OF CALIFORNIA SAN FRANCISCO
|
|
|
Viral Proteins: Gene Delivery to Specific Malignancies
|
5R01CA081171-07
|
$249,183
|
$249,183
|
ALBRITTON, LORRAINE
|
UNIVERSITY OF TENNESSEE HEALTH SCI CTR
|
|
|
DNA Methylation and GSTP1 Gene Regulation in Gliomas
|
5R01CA091438-06
|
$322,675
|
$161,338
|
Ali-Osman, Francis
|
DUKE UNIVERSITY
|
|
|
Novel Targeted Therapeutics for CNS Malignancies
|
5R01CA112519-02
|
$324,799
|
$324,799
|
Ali-Osman, Francis
|
DUKE UNIVERSITY
|
|
|
Control of apoptosis in cancer by survivin
|
5R01CA078810-11
|
$283,430
|
$93,532
|
Altieri, Dario
|
UNIV OF MASSACHUSETTS MED SCH WORCESTER
|
|
|
Prediction and assessment of response to targated therapy in pancreatic cancer
|
7R21CA123888-02
|
$224,748
|
$224,748
|
ALTIOK, SONER
|
H. LEE MOFFITT CANCER CTR & RES INST
|
|
|
PRECLINICAL PHARMACOLOGICAL STUDIES OF ANTITUMOR AND OTHER THERAPEUTIC AGENTS
|
N01CM522006-007
|
$184,964
|
$184,964
|
AMES, MATTHEW
|
MAYO CLINIC ROCHESTER
|
|
|
NANOTHERAPEUTIC STRATEGY FOR MULTIDRUG RESISTANT TUMORS
|
5R01CA119617-03
|
$359,916
|
$359,916
|
AMIJI, MANSOOR
|
NORTHEASTERN UNIVERSITY
|
|
|
Universal Technology for Profiling the Dynamics of Normal & Oncogenic Signaling
|
1R21CA125284-01A1
|
$198,587
|
$99,294
|
ANDERSON, KAREN
|
YALE UNIVERSITY
|
|
|
Santa Rosa Memorial Hospital Regional CCOP
|
3U10CA063850-12S2
|
$131,400
|
$1,314
|
ANDERSON, IAN
|
SANTA ROSA MEMORIAL HOSPITAL
|
|
|
Host-Tumor Cell Interactions in Myeloma:
|
5P01CA078378-10
|
$2,008,736
|
$662,883
|
ANDERSON, KENNETH
|
DANA-FARBER CANCER INSTITUTE
|
|
|
Specialized Program of Research Excellence in Myeloma
|
5P50CA100707-05
|
$2,136,145
|
$1,708,916
|
ANDERSON, KENNETH
|
DANA-FARBER CANCER INSTITUTE
|
|
|
Role of Cytokines in Myeloma Pathogenesis
|
5R01CA050947-16
|
$283,743
|
$141,872
|
ANDERSON, KENNETH
|
DANA-FARBER CANCER INSTITUTE
|
|
|
Children's Oncology Group Statistics and Data Center
|
5U10CA098413-05
|
$5,859,839
|
$292,992
|
ANDERSON, JAMES
|
NATIONAL CHILDHOOD CANCER FOUNDATION
|
|
|
THE THERAPY OF AML
|
2P01CA055164-15A1
|
$2,404,845
|
$1,202,423
|
ANDREEFF, MICHAEL
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
|
High Throughput Screen for Compounds to Treat Papillomavirus Induced Cancers
|
5R21CA121927-02
|
$119,919
|
$119,919
|
ANDROPHY, ELLIOT
|
UNIV OF MASSACHUSETTS MED SCH WORCESTER
|
|
|
Extension of Radiotherapy Research
|
5P01CA006294-43
|
$1,506,020
|
$301,204
|
ANG, K
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
|
BLys inhibition using TACI-Fc in patients with B-bell non-Hodgkins' Lymphoma
|
1R21CA121569-01A1
|
$281,200
|
$281,200
|
ANSELL, STEPHEN
|
MAYO CLINIC COLL OF MEDICINE, ROCHESTER
|
|
|
GENETIC PREDICTORS OF LEUKEMIA THERAPY RESPONSE
|
5R01CA108862-03
|
$256,930
|
$256,930
|
Aplenc, Richard
|
CHILDREN'S HOSPITAL OF PHILADELPHIA
|
|
|
Adult Leukemia Research Center
|
2P01CA018029-32
|
$5,086,500
|
$508,650
|
APPELBAUM, FREDERICK
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
|
Reversal of 5-FU Resistance by Arsenic Trioxide in Colorectal Carcinoma
|
1R21CA117116-01A2
|
$290,541
|
$290,541
|
ARDALAN, BACH
|
UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
|
|
|
SPORE in Breast Cancer
|
5P50CA098131-05
|
$2,360,642
|
$1,770,482
|
ARTEAGA, CARLOS
|
VANDERBILT UNIVERSITY
|
|
|
TGF-betas and Receptors and Human Breast Cells
|
5R01CA062212-12
|
$327,034
|
$65,407
|
ARTEAGA, CARLOS
|
VANDERBILT UNIVERSITY
|
|
|
Erbb2 targeted antitumor strategies in breast cancer
|
5R01CA080195-09
|
$302,816
|
$302,816
|
ARTEAGA, CARLOS
|
VANDERBILT UNIVERSITY
|
|
|
Eastern Cooperative Oncology Group
|
2U10CA080775-09
|
$128,678
|
$11,581
|
ATKINS, MICHAEL
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
Southeast Cancer Control Consortium, Inc
|
3U10CA045808-21S1
|
$170,000
|
$3,400
|
ATKINS, JAMES
|
SOUTHEAST CANCER CONTROL CONSORTIUM
|
|
|
DF/HCC Renal Cancer SPORE
|
5P50CA101942-05
|
$2,330,598
|
$1,398,359
|
ATKINS, MICHAEL
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
Southeast Cancer Control Consortium, Inc
|
5U10CA045808-21
|
$1,860,642
|
$37,213
|
ATKINS, JAMES
|
SOUTHEAST CANCER CONTROL CONSORTIUM
|
|
|
Telomeres, telomerase and chemotherapy: Bench to bedside
|
2R01CA077091-04A2
|
$312,217
|
$312,217
|
Au, Jessie
|
OHIO STATE UNIVERSITY
|
|
|
anti-tumor activity of deactylase inhibitors
|
5R01CA102746-04
|
$271,505
|
$271,505
|
AVANTAGGIATI, MARIA
|
GEORGETOWN UNIVERSITY
|
|
|
Eastern Cooperative Oncology Group Studies
|
5U10CA014548-33
|
$413,938
|
$37,254
|
AVERBOOK, BRUCE
|
CASE WESTERN RESERVE UNIVERSITY
|
|
|
Mechanism of Drug Transport in Lung Cancer Cells
|
2R01CA077495-09A1
|
$250,594
|
$250,594
|
Awasthi, Sanjay
|
UNIVERSITY OF TEXAS ARLINGTON
|
|
|
Role of RALBP1 in Xenobiotic and Radiation Resistance
|
5R01CA104661-04
|
$258,910
|
$129,455
|
Awasthi, Sanjay
|
UNIVERSITY OF TEXAS ARLINGTON
|
|
|
Oxidative Pentose Cycle in Hypoxic Cancer Cell Response
|
5R01CA109604-04
|
$247,193
|
$247,193
|
AYENE, IRAIMOUDI
|
LANKENAU INSTITUTE FOR MEDICAL RESEARCH
|
|
Total relevant funding to Orphan Drug Research for this search: $569,996,227
|
